MigraineA Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine - PIONEER-PEDS1 - Eli Lilly and Company
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine - REBUILD-1 - Eli Lilly and Company
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine - REBUILD-2 - Eli Lilly and Company